Ahmed Hassanein

Mr. Ahmed Hassanein


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
HRHumam Rajha
Humam Rajha
AHAhmed Hassanein
Ahmed Hassanein
RMRowan Mesilhy
Rowan Mesilhy
ZNZainab Hafez Nurulhaque
Zainab Hafez Nurulhaque
NENebras Elghoul
Nebras Elghoul
Shona Dr. Shona PedersenShona Dr. Shona Pedersen
Shona Dr. Shona Pedersen
Apolipoprotein A (ApoA) proteins, ApoA-I, ApoA-II, ApoA-IV, and ApoA-V, play critical roles in lipid metabolism, neuroinflammation, and blood–brain barrier integrity, making them pivotal in neurological diseases such as Alzheimer’s disease (AD), stroke, Parkinson’s disease (PD), and multiple sclerosis (MS). This review synthesizes current evidence on their structural and functional contributions to neuroprotection, highlighting their dual roles as biomarkers and therapeutic targets. ApoA-I, the most extensively studied, exhibits anti-inflammatory, antioxidant, and amyloid-clearing properties, with reduced levels associated with AD progression and cognitive decline. ApoA-II modulates HDL metabolism and stroke risk, while ApoA-IV influences neuroinflammation and amyloid processing. ApoA-V, although less explored, is implicated in stroke susceptibility through its regulation of triglycerides. Genetic polymorphisms (e.g., APOA1 rs670, APOA5 rs662799) further complicate disease risk, showing population-specific associations with stroke and neurodegeneration. Therapeutic strategies targeting ApoA proteins, including reconstituted HDL, mimetic peptides, and gene-based approaches, show promise in preclinical models but face translational challenges in human trials. Clinical trials, such as those with CSL112, highlight the need for neuro-specific optimization. Further research should prioritize human-relevant models, advanced neuroimaging techniques, and functional assays to elucidate ApoA mechanisms inside the central nervous system. The integration of genetic, lipidomic, and clinical data offers potential for enhancing precision medicine in neurological illnesses by facilitating the generation of ApoA-targeted treatments and bridging current deficiencies in disease comprehension and therapy.

19 March 2025 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
AHAhmed Hassanein
Ahmed Hassanein
SASaghir Akhtar
Saghir Akhtar
Type 1 diabetes mellitus (T1DM) is a serious, chronic metabolic and autoimmune disease that affects millions globally. While insulin administration remains the most effective treatment, it is not a cure. Long-term therapies, such as immunotherapy, can be effective for some patients, but they have notable limitations and do not provide a permanent solution. As a result, current research has shifted towards stem cell-based therapies, which offer a potentially expandable and scalable source of pancreatic beta cells. These therapies aim to restore long-term endogenous β-cell function in all T1DM patients, provided they can avoid immune recognition and rejection by the host. In this review, we will discuss the latest first-in-human successes of stem cell therapies for T1DM. We will then explore stem cell-derived islet encapsulation technologies and hypoimmune stem cells, examining how they might overcome the need for immunosuppressive therapy. Additionally, we will provide a summary of recent and ongoing biopharmaceutical industry pipelines and clinical trials for stem cell therapies aimed at treating T1DM. These advances suggest that stem cell therapies offer a promising and highly effective approach to treating patients with this chronic disease. However, large-scale clinical trials over the long term are necessary to verify these early successes and assess the curative potential of stem cell therapy for T1DM.

3 April 2026 in Annals of Medicine
Verified
Journal Article
Open access
AHAhmed Hassanein
Ahmed Hassanein
SASaghir Akhtar
Saghir Akhtar
Endothelial dysfunction, a hallmark of diabetic vascular complications, is thought to arise from hyperglycemia-induced oxidative stress and inflammation within endothelial cells. However, accumulating evidence suggests that red blood cells (RBCs), beyond serving as passive oxygen carriers, actively contribute to vascular pathology by communicating detrimental changes to the endothelium eliciting endothelial dysfunction. This review critically evaluates the mechanistic role of RBCs in mediating endothelial dysfunction in diabetes, focusing on three key questions. First, what pathological alterations occur in diabetic RBCs that promote endothelial dysfunction? Key diabetes-induced changes within RBCs that have been implicated in endothelial dysfunction include enhanced arginase-1 activity, RBC eNOS uncoupling, glycation-induced structural modifications structural modifications (e.g. reduced deformability and increased aggregation), shedding of pathological extracellular vesicles (RBC-EVs), and loss of protective signals such as ATP and MicroRNAs (e.g. miR-210 and miR-210-3p). Second, how do anucleate RBCs acquire these pathological alterations? In addition to the direct metabolic effects of hyperglycemia, we discuss other possibilities including bidirectional vesicular exchange between RBCs and endothelial cells. Third, how are these pathological signals transmitted from RBCs to the endothelium? We discuss four possible routes of communication including direct ligand-receptors interactions, paracrine signaling, direct physico-mechanical perturbations, and vesicular transport via RBC-EVs. Diabetes induces many pathological alterations within RBCs which have been shown to be transmitted to endothelial cells and elicit endothelial dysfunction. The role of RBCs as key players in eliciting endothelial dysfunction represent a major paradigm shift in our understanding of diabetes-induced vascular dysfunction and thus, RBCs might represent a novel therapeutic target in cardiovascular disease.

22 August 2026 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
AHAhmed Hassanein
Ahmed Hassanein
SASaghir Akhtar
Saghir Akhtar

25 April 2026 in Genes
Verified
Journal Article
Open access
PDF file
GAGhaya Ibrahim Alrumaihi
Ghaya Ibrahim Alrumaihi
Md. Shaheenur Islam SumonMd. Shaheenur Islam Sumon
Md. Shaheenur Islam Sumon
AHAhmed Hassanein
Ahmed Hassanein
MMMarwan Qutaibah Malluhi
Marwan Qutaibah Malluhi
SHSakib Abrar Hossain
Sakib Abrar Hossain
Shona Dr. Shona PedersenShona Dr. Shona Pedersen
Shona Dr. Shona Pedersen
Background: Gliomas are among the most common and heterogeneous primary brain tumors, exhibiting substantial molecular and transcriptomic diversity that complicates diagnosis, grading, and treatment planning. Advances in artificial intelligence (AI), particularly machine learning (ML), offer powerful opportunities to analyze high-dimensional gene expression data and support precision oncology. Methods: This study proposes an interpretable ML framework to classify brain tumor subtypes—glioblastoma, astrocytoma, and oligodendroglioma—and to predict tumor grades (2, 3, and 4) using microarray-based gene expression data. The analysis was conducted on the REMBRANDT dataset, comprising 464 labeled samples (221 glioblastoma, 148 astrocytoma, 67 oligodendroglioma, and 28 controls) and 314 tumor samples for grade classification. Results: The ML models achieved high performance for disease classification, with accuracies of 99.6% (AUC 99.89%) for glioblastoma, 98.3% (AUC 99.83%) for astrocytoma, and 98.95% (AUC 100%) for oligodendroglioma. Tumor grade predictions also performed strongly, achieving 83.7% accuracy (AUC 88.2%) for grade II vs. III, 91.3% (AUC 94.8%) for grade II vs. IV, and 84.2% (AUC 90.8%) for grade III vs. IV. SHAP analysis identified key genes contributing to the model predictions (e.g., WIF1, STX6, RGS5, and ACTR2), and KEGG enrichment identified the candidate pathways involved in vesicular transport, metabolism, and immune signaling. Conclusion: Overall, our findings demonstrate that interpretable ML models can accurately differentiate glioma subtypes and grades, and SHAP analysis can help identify the strongest predictors of our models. These findings provide additional insights into the heterogeneous genetic and molecular landscape of brain gliomas and are intended to complement, not replace, conventional histopathological diagnosis.

12 October 2026 in Angiology
Verified
Journal Article
Closed access
AHAhmed Hassanein
Ahmed Hassanein
HRHumam Rajha
Humam Rajha
MHMohammed Abdel Hamid
Mohammed Abdel Hamid
IHIbrahim E. Hashem
Ibrahim E. Hashem
RSRafif Mahmood AL Saady
Rafif Mahmood AL Saady
SPShona Pedersen
Shona Pedersen
Apolipoprotein A (ApoA) family members—ApoA-I, ApoA-II, ApoA-IV, and ApoA-V—play important roles in the vasculature that extend beyond lipid transport to regulate lipid-immune crosstalk, vascular homeostasis, and triglyceride metabolism. ApoA-I mediates reverse cholesterol transport, yet its cardioprotective capacity depends on functional integrity rather than HDL-cholesterol levels alone. ApoA-II, ApoA-IV, and ApoA-V exhibit context-dependent roles ranging from enhancing cholesterol efflux and triglyceride clearance to modulating inflammation, oxidative stress, endothelial activation, and thrombosis. Post-translational modifications such as oxidation, glycation, and citrullination within inflammatory milieus can convert protective ApoA proteins into dysfunctional or proinflammatory mediators. Genetic variations within APOA gene clusters have clarified the causal contribution of triglyceride-rich lipoproteins to atherosclerotic risk, shifting emphasis from HDL quantity toward lipoprotein quality and remnant cholesterol burden. In this comprehensive review, we synthesize structural, genetic, mechanistic, and clinical evidence to evaluate the position of the 4 ApoA proteins as context-dependent modulators of cardiovascular disease. We highlight the dualistic nature of their actions and examine failed clinical trials of ApoA-I infusions and mimetic peptides. We conclude by discussing how shifting focus from HDL quantity toward lipoprotein quality and preservation of ApoA functional integrity may inform more precise approaches to residual cardiovascular risk and triglyceride-driven atherogenesis.